ERBB2 and breast cancer: Several factors have been speculated to contribute to the HER2-low expression in BC including the bi-directional crosstalk between ER and HER2, the modification effect by endocrine therapy, and the activation of NF-kB pathway by chemotherapy and radiation therapy [11].